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Do Positive Inotropic Agents Adversely Affect the Survival of Patients
With Chronic Congestive Heart Failure?
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No class of drugs for the treatment of congestive heart
failure has generated as much passion as the oral inotropic
agents . The first exciting reports that synthetic pharmaco-
logic agents unrelated to digitalis or the catecholamines
could stimulate cardiac contractility appeared in 1978 (I) .
These
initial investigations (2) indicated that these new
inotropic agents could produce dramatic short-term hemo-
dynamic benefits in patients with advanced left ventricular
dysfunction . Yet, 10 years have passed since the publication
of these exciting findings, but thus far, no new orally active
positive inotropic drug has been approved for the treatment
of chronic congestive heart failure .
The available oral nonglycoside inotropic agents . It is of
historic interest that the initial favorable reports of the
effects of the new nonglycoside inotropic agents coincided
with early studies of the hemodynamic effects of captopri) in
hypertension (3) and of teprotide in patients with severe left
ventricular dysfunction
(4),
which suggested that converting
enzyme inhibitors held promise for the treatment of conges-
tive heart failure (4) . During the next decade, however, the
development of these two classes of drugs followed totally
different courses (Fig . 1). The converting enzyme inhibitors
have achieved widespread acceptance in the medical com-
munity in view of overwhelming evidence that these drugs
can produce important short- and long-term hemodynamic
and symptomatic benefits and can reduce the mortality of
patients with chronic heart failure (54). In contrast, increas-
ing doubts have been raised about the safety and efficacy of
long-term therapy with the new positive inotropic agents,
particularly those drugs that increase intracellular cyclic
adenosine monophosphate (AMP) by inhibiting myocardial
phosphodiesterase . Despite early promising results, the first
phosphodiesterase inhibitor. amrinone, was withdrawn from
clinical investigation because its unfavorable side effect
profile prevented the administration of doses of the drug that
were large enough to produce clinical improvement (9). The
dramatic hemodynamic benefits of the imidazole derivatives
(enoximone and piroximone) were accompanied by consid-
erable gastrointestinal intolerance (10-12) . The development
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of milrinone, a second generation bypyridine derivative,
demonstrated that positive inotropic effects could be
achieved with few adverse effects on the gastrointestinal
tract (13,14), but the introduction of this agent coincided
with a heightened awareness in the medical community that
pharmacologic interventions could (and in fact, should)
improve the survival of patients with congestive heart fail-
w e .
Do positive inotropic drugs influence survival in chronic
heart failure? The first patients with heart failure to be
treated with the new phosphodiesterase inhibitors had very
severe heart failure; many had previously been unsuccess-
fully treated with vasodilators and converting enzyme inhib-
itors (14,15). The high mortality rate (14-17) of these patients
should not have been surprising; nevertheless, it proved to
be an enormous source of frustration for clinical investiga-
tors, who hoped that the impressive hemodynamic benefits
seen after short-term treatment with amrinone and milrinone
would be translated into prolonged clinical remission . When
anecdotal experience suggested that patients who had ben-
efited from treatment with these agents had an unexpectedly
high mortality, concerns were raised regarding a potential
deleterious effect of oral inotropic therapy . In the absence of
a control group, however, it was difficult for any investigator
to identify a direct adverse effect.
Nevertheless, the concerns of the cardiology community
regarding the long-term consequences of positive inotropic
therapy continued to grow . In part, these concerns were
based on data from the experimental laboratory. All of the
phosphodiesterase inhibitors appeared to act by increasing
the intracellular level of cyclic AMP within the failing
myocardium (18), but a high tissue concentration of this
nucleotide was known to be toxic to the myocardium and
had been implicated in the pathogenesis of experimental
arrhythmias (19) . Furthermore, long-term positive inotropic
stimulation could be expected to increase energy expendi-
tures in the failing heart and might thereby accelerate
progression of the underlying disease . These theoretical
fears were raised simultaneously with the publication of the
first clinical report of amrinone (20) .
These concerns about the long-term consequences of
positive inotropic therapy were underscored by reports from
the clinical laboratory. For example, in a number of uncon-
trolled studies, we (21) and others (22) noted that therapy
with milrinone was associated with an increase in the fre-
quency of ventricular arrhythmias . This observation raised
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Figure 1
. Schematic representing enthusiasm for either oral intro.
pie agents or angiotensin-converting enzyme (ACE) inhibitors as a
portion of 163%
enthusiasm. This demonstrates a progressively
greater share of enthusiasm for ACE inhibitors, particularly
siren
1982, when efficacy data resulted in the approval of caplopril by the
Food and Drug Administration (FDA) .
immediate fears, because high grade ventricular arrhythmias
were known to be an independent determinant of mortality
in patients with heart failure (23,24) . This observation was
coupled with reports (16,25) that suggested that long-term
phosphodiesterase inhibition was accompanied by progres-
sion of the underlying disease, despite evidence for continued
drug-related hemodynamic improvement. It was difficult,
however, to be certain that these adverse hemodynamic and
electrophysiologic effects were directly related to the admin-
istralion of positive inotropic drags rather than being a natural
consequence of the severity of the disease .
Clinical studies that demonstrated that the phosphodies-
terase inhibitors exerted direct vasodilating effects (26,27)
have frsrther heightened the controversy. These reports
suggested that most of the hemodynamic actions of milri-
none could be attributed to the drug's peripheral vasedilating
effects
. A few observers(28,29) even doubted whether this
class of drugs could elicit a clinically relevant positive
inotropic response in diseased segments of the myocardium,
which are depleted of cyclic AMP . Yet, if the phosphodies-
terase inhibitors act primarily as vasodilators
. then these
drugs should prolong life in patients with chronic heart
failure, as do other vasodilators (8,30). However, a favorable
effect on mortality has not been demonstrated with oral
inotropic agents
. Some investigators believe that such a
beneficial effect is unlikely and suggest that the adverse
myocardial and electrophysiologic actions of the inotropic
drugs offset their favorable vasodilating actions. Uncon-
trolled studies appear to support this point of view
(14,16,17,25).
There is little doubt that the continuing controversy about
the effect of positive inotropic drugs on the survival of
patients with chronic heart failure can only be resolved by
the results of large scale, controlled, randomized clinical
trials that are designed specifically to address this issue .
Such trials have not yet been carried on(, but new data are
now available from small controlled studies that might
I
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provide some new insights into this controversial area .
These recently completed studies are discussed in depth by
Colucci and Packer in the following artidee .
Is there a need for an orally active positive inotropic agent?
Despite the dramatic benefits that generally accompany
treatment with the converting enzyme inhibitors, many
patients with chronic heart failure fail to respond favorably
to these drugs or experience an adverse reaction that limits
long-term therapy
. The favorable effects of the converting
enzyme inhibitors on mortality in chronic heart failure now
permit patients to live longer but, as they do so, patients
commonly reach a stage in their disease process when the
magnitude of symptomatic improvement appeals to be at-
tenuated . Such patients represent the most critically ill
patients end are frequently referred to centers specializing in
heart failure research . Their increasing prevalence indicates
that we have not achieved optimal therapeutic control of the
heart failure process. It is in the context of this therapeutic
void that orally active positive isotropic agents may provide
some benefit
.
It is not clear, however, that the new positive inotropic
agents can fill this therapeutic void . Although the clinical
utility of short-term intravenous positive inotropic therapy is
well established in the management of acute heart failure or
cardiogenic shock, there are few data that convincingly
demonstrate the long-term efficacy of the phosphodiesterase
inhibitors in chronic heart failure
. The lack of such data
should not yet he viewed with undue pessimism . The debate
regarding the efficacy of digitalis has persisted for 2 centuries
(31). It is only recently that compelling evidence has become
available that demonstrates a favorable effect of digoxin in
patients with chronic heart failure in normal sinus rhythm
(32,33). Yet, a review of the early enthusiasm and subse-
quent disillusionment that followed the introduction of oral
beta-adrenergic agenists should remind us that not all posi-
tive inotropic agents are destined to find a place in the
management of chronic heart failure (34,35) .
if the new phosphodiesterase inhibitors
prove
to be
effective in the treatment of heart faihrre, what will he their
rule? These agents would appear to be desirable for the
treatment of patients with the most severe symptoms, par-
ticularly those individuals who have been unsuccessfully
treated with conventional vasodilators and converting en-
zyme inhibitors. On the other hand, if these drugs do not
improve or actually shorten survival . their use will probably
be relegated to the short-term circulatory support of patients
awaiting cardiac transplantation .
Conclusions. The role of the new positive inotropic
agents in the treatment of chronic heart failure remains
undefined . In contrast to the development of converting
enzyme inhibitors, that of the phosphodiesterase inhibitors
has been marked by persistent concerns about their efficacy
and safety
. More clear-cut evidence of efficacy and safety
will be required ; if such evidence is not forthcoming, this
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class of drug will probably never be approved for the
treatment of chronic heart failure . It is not clear, however,
that all future positive isotropic agents will be greeted by the
skepticism that has accompanied the development of the
phosphodiesterase inhibitors . It is possible that new ap-
proaches to the design
of
inotropic drugs (calcium sensiti2a-
tion,
for example) can be developed on the basis of an
evolving understanding of the cellular and biochemical ab-
normalities in heart failure . Such creative solutions may lead
to important therapeutic advances .
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